Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ecallantide (Dyax/Genzyme).

Andreas Lehmann1

  • 1Department of Anesthesiology and Intensive Care Medicine, Klinikum der Stadt Ludwigshafen, Germany. lehmanna@klilu.de

Current Opinion in Investigational Drugs (London, England : 2000)
|March 25, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Precipitation as key parameter for early oral drug absorption predictions, Part I: Acquisition of critical data.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2025
Same author

Precipitation as key parameter for early oral drug absorption predictions, Part II: Development of a predictive model.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2025
Same author

Comparative assessment of binding and functional differences of clinical antibodies targeting α-synuclein in cellular models of Parkinson's disease.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2025
Same author

Climate challenges for fish larvae: Interactive multi-stressor effects impair acclimation potential of Atlantic herring larvae.

The Science of the total environment·2024
Same author

Analyzing parametric influences driving age-associated changes in absorption using a PBPK-GSA approach.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2024
Same author

Early arrival of spring-spawning Atlantic herring Clupea harengus at their spawning ground in the Kiel Fjord, western Baltic, relates to increasing winter seawater temperature.

Journal of fish biology·2024
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Ecallantide, a kallikrein inhibitor, is being developed for hereditary angioedema and to reduce blood loss during surgery. Clinical trials for both applications are underway, with a phase III trial for HAE starting in late 2005.

Area of Science:

  • Pharmacology
  • Biotechnology
  • Clinical Medicine

Background:

  • Ecallantide is a small-protein kallikrein inhibitor developed using phage display technology.
  • It is being investigated as a subcutaneous treatment for hereditary angioedema (HAE).
  • Ecallantide is also being developed for reducing blood loss during cardiopulmonary bypass surgery.

Purpose of the Study:

  • To evaluate ecallantide as a potential treatment for hereditary angioedema.
  • To assess the efficacy of ecallantide in reducing peri-operative blood loss during cardiopulmonary bypass surgery.

Main Methods:

  • Phage display technology was used for the identification of ecallantide.
  • Phase II and Phase III clinical trials are being conducted to evaluate its safety and efficacy.

Related Experiment Videos

Main Results:

  • A pivotal Phase III clinical trial for HAE commenced in December 2005.
  • Phase II trials for surgical application faced delays due to partnership negotiations.

Conclusions:

  • Ecallantide shows promise as a therapeutic agent for both HAE and surgical bleeding.
  • Ongoing clinical trials will determine its ultimate clinical utility.